COVID-19 vaccine next month after final trial results showed it had a 95% success rate and no serious side effects, the drugmakers said on Wednesday.The efficacy of the shot was found to be consistent across different ages and ethnicities - a promising sign given the disease has disproportionately affected the elderly and certain groups including Black people.The U.S.
Food and Drug Administration could grant emergency-use approval towards the end of the first half of December or early in the second half, BioNTech Chief Executive Ugur Sahin told Reuters TV.